Baili Tianheng (688506.SH): GNC-077 monoclonal antibody injection for the treatment of advanced solid tumors has obtained the Phase I clinical trial approval notification.

15:34 22/09/2024

Baili Tianheng (688506.SH) announced that the company has recently received approval from the National Medical Products Administration (NMPA)...

Baoli Tianheng (688506.SH) announced that the company recently received the official approval letter for the clinical trial of the company's independently developed innovative biopharmaceutical GNC-077 from the National Medical Products Administration (NMPA). According to the "Drug Administration Law of the People's Republic of China" and relevant regulations, the clinical trial application for GNC-077 multi-specific antibody injection, which was accepted on July 16, 2024, meets the relevant requirements for drug registration, and the company has been authorized to conduct clinical trials for late-stage solid tumors.

Sinolink: Looking at the real estate market from the perspective of "Little Spring", it is expected to reach the bottom.

Sinolink: Escalation of US-Iran conflict reverses "weak US dollar" narrative, strong assets may help reverse market decline and indicate a bottom.

Huachuang Securities: Under the impact of high oil prices in this round, the middle and upper reaches of the profit margin may have more resilience.

Sinolink: Looking at the real estate market from the perspective of "Little Spring", it is expected to reach the bottom.

Sinolink: Escalation of US-Iran conflict reverses "weak US dollar" narrative, strong assets may help reverse market decline and indicate a bottom.

Huachuang Securities: Under the impact of high oil prices in this round, the middle and upper reaches of the profit margin may have more resilience.